Ventricular hypertrophy and cavity dilatation in relation to body mass index in women with uncomplicated obesity

Heart

Volumn 97, Issue 3, 2011, Pages 203-208

  Rider, Oliver J ^a   Petersen, Steffen E ^a   Francis, Jane M ^a   Ali, Mohammed K ^a   Hudsmith, Lucy E ^a   Robinson, Monique R ^a   Clarke, Kieran ^a   Neubauer, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LEPTIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; BODY MASS INDEX; CARDIOMEGALY; COHORT STUDIES; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR; INSULIN; INSULIN RESISTANCE; LEPTIN; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OBESITY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 78651236282     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.185009     Document Type: Article

References (28)

1. Alexander JK. Obesity and the heart. Heart Dis Stroke 1993;2:317-21.
2. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001;321:225-36.
3. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.
4. Rider OJ, Francis JM, Ali MK, et al. Determinants of left ventricular mass in obesity; a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2009;11:9.
5. Ku CS, Lin SL, Wang DJ, et al. Left ventricular filling in young normotensive obese adults. Am J Cardiol 1994;73:613-15.
6. Messerli FH. Cardiopathy of obesity - a not-so-Victorian disease. N Engl J Med 1986;314:378-80.
7. Perego L, Pizzocri P, Corradi D, et al. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. J Clin Endocrinol Metab 2005;90:4087-93.
8. Tajmir P, Ceddia RB, Li RK, et al. Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase- and phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology 2004;145:1550-5.
9. Rajapurohitam V, Gan XT, Kirshenbaum LA, et al. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003;93:277-9.
10. Abe Y, Ono K, Kawamura T, et al. Leptin induces elongation of cardiac myocyte and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 2007;292:H2387-96.
11. Myerson SG, Montgomery HE, World MJ, et al. Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension 2002;40:673-8.
12. Duncan MH, Singh BM, Wise PH, et al. A simple measure of insulin resistance. Lancet 1995;346:120-1.
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
14. Hudsmith LE, Petersen SE, Francis JM, et al. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 2005;7:775-82.
15. Petersen SE, Wiesmann F, Hudsmith LE, et al. Functional and structural vascular remodeling in elite rowers assessed by cardiovascular magnetic resonance. J Am Coll Cardiol 2006;48:790-7.
16. Rider OJ, Francis JM, Ali MK, et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J Am Coll Cardiol 2009;54:718-26.
17. Cittadini A, Stromer H, Katz SE, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996;93:800-9.
18. Faggioni R, Fantuzzi G, Fuller J, et al. IL-1 beta mediates leptin induction during inflammation. Am J Physiol 1998;274:R204-8.
19. Purdham DM, Zou MX, Rajapurohitam V, et al. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol 2004;287:H2877-84.
20. Madani S, De Girolamo S, Munoz DM, et al. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 2006;69:716-25.
21. Zeidan A, Javadov S, Karmazyn M. Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc Res 2006;72:101-11.
22. Banks AS, Davis SM, Bates SH, et al. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000;275:14563-72.
23. Ghilardi N, Skoda RC. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol 1997;11:393-9.
24. Larsen GC, Griffith JL, Beshansky JR, et al. Electrocardiographic left ventricular hypertrophy in patients with suspected acute cardiac ischemia - its influence on diagnosis, triage, and short-term prognosis: a multicenter study. J Gen Intern Med 1994;9:666-73.
25. Levy D, Anderson KM, Savage DD, et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988;108:7-13.
26. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001;141:334-41.
27. Fang J, Wylie-Rosett J, Cohen HW, et al. Exercise, body mass index, caloric intake, and cardiovascular mortality. Am J Prev Med 2003;25:283-9. (Pubitemid 37346148)
28. Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;116:627-36.